Intermittent Fasting for Pancreatic Cancer Risk

This trial explores whether individuals at high risk for pancreatic cancer can adhere to an eating pattern called intermittent fasting (IF) and how it affects their health. Participants will fast for 16 hours daily and eat during an 8-hour window. The study aims to determine if this eating style alters biological markers related to metabolism, inflammation, gut health, and more. Suitable candidates may have a family history of pancreatic cancer, certain genetic conditions, pancreatic cysts, or new-onset diabetes considered suspicious for cancer. Participants should be willing to adjust their eating schedule and track fasting times with an app. As an unphased trial, this study offers a unique opportunity to contribute to groundbreaking research on dietary patterns and cancer risk.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research has shown that intermittent fasting (IF) is generally safe for most people, including those with cancer. Studies have found that individuals can follow this eating pattern with few side effects. For instance, participants report adhering well to fasting without suffering from malnutrition and experiencing only minor negative effects. Additionally, fasting might improve health measures like insulin sensitivity and blood sugar levels, which benefit overall health.

Unlike the standard treatments for reducing pancreatic cancer risk, which often involve medications or surgery, intermittent fasting is a lifestyle change that focuses on when you eat, not what you eat. Researchers are excited about intermittent fasting because it taps into the body's natural metabolic processes, potentially lowering cancer risk without the need for drugs or invasive procedures. This approach is non-invasive, easy to implement, and may offer a new way to help manage cancer risk by leveraging the body's own biology.

Studies have shown that intermittent fasting (IF) might help reduce cancer risk. Research suggests that fasting can lower blood sugar levels and improve insulin use, which links to a reduced chance of developing cancer. Some studies also indicate that IF can lessen chemotherapy side effects and slow tumor growth. Early findings suggest that fasting may be safe for cancer patients and could help prevent cancer recurrence. While more research is needed, these initial insights suggest potential benefits of intermittent fasting for those at risk of pancreatic cancer. Participants in this trial will follow an intermittent fasting regimen, fasting for 16 consecutive hours each day with an 8-hour eating window, to evaluate its effects on pancreatic cancer risk.¹³⁶⁷⁸